ABCL is experiencing significant momentum and upward movement. The post lacks specific fundamental analysis or catalysts, relying primarily on enthusiasm about price action.

ABCL is a Canadian biotech with a Phase 2 readout expected Q3 2026 for ABCL-635 (hot flash treatment) in a ~$6B market, backed by $655M liquidity and 4-5 years of runway without dilution risk. Binary event catalyst with management calling it their most important readout ever, but carries 40-50% downside risk if Phase 2 misses.